Now, experts hope a vaccine can help contain a new outbreak of the virus in Congo — a simple intervention that could have saved thousands of lives had it been ready in 2014.
On Friday, the World Health Organization announced its plan to send the experimental vaccine to northwest Congo, where there have been about 32 suspected or confirmed cases since early April and 18 deaths.
“We are very concerned and planning for all scenarios, including the worst-case scenario,” Peter Salama, the WHO’s deputy director-general of emergency preparedness and response, said in Geneva on Friday.
Challenges will include keeping the vaccine at low temperatures in Congo's heat and with the lack of infrastructure in the rural area, as well as getting the vaccine to those who have been exposed to the virus. Despite it occurring outside an urban area, this particular outbreak may be harder to contain because it has already spread across 37 miles. Some of those infected are health workers, which poses an additional risk of transmission to others. Those who help bury or clean the bodies of the infected are also at high risk.
Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, told The Washington Post that Ebola outbreaks are dangerous in an increasingly urbanizing Africa because once infections spread to a metropolitan area, they become much more difficult to control. Already, officials in Congo fear that the virus could spread to the provincial capital Mbandaka, home to about 1 million people.
“All it would take is one or two of these infected individuals to go into a larger metropolitan area,” Osterholm said. When it comes to the danger of a large outbreak, “Kinshasa is a gas tanker waiting for a match to hit it,” he added. The Congolese capital's population of 14 million means the disease would spread very quickly if it reaches the city, which is far from the affected area.
On Friday, Salama said he had spoken to Congo's health minister and hoped that he would soon have approval to use the vaccine, which was developed by Merck in 2016. In a trial of 11,800 people in Guinea in 2015, the vaccine had 100 percent efficacy, giving hope it could be a game-changer in preventing Ebola from spreading.
Researchers there used the same approach that was used to study smallpox, where they identified a “ring” of people who may have come into contact with an infected person and then vaccinated all of them after determining they may have been at risk. The side effects were mostly mild.
Congo has suffered a number of Ebola outbreaks in recent years but has largely managed to contain them. A 2014 outbreak killed 49 people. In this case, the vaccine's deployment is intended to assist health-care workers in ending the outbreak long before it has the possibility of turning into an epidemic.